Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
Metrics: PDF 1959 views | ?
1 University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Birmingham, AL, USA
2 University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, AL, USA
3 Southern Research Institute, Department of Oncology, Birmingham, AL, USA
4 University of Alabama at Birmingham, Department of Pathology, Division of Molecular & Cellular Pathology, Birmingham, AL, USA
5 Ohio State University, Department of Medicinal Chemistry and Pharmacognosy, Columbus, OH, USA
6 University of Virginia, Department of Oncology, Division of Gynecologic Oncology, Charlottesville, VA, USA
7 University of Alabama at Birmingham, Department of Epidemiology, Birmingham, AL, USA
8 University of Alabama at Birmingham, Department of Medicine, Division of Hematology & Oncology, Birmingham, AL, USA
Published: April 10, 2018
This article has been corrected: The correct Funding information is given below:
NIH grant support in the Comprehensive Flow Cytometry Core (CFCC) (P30 AR48311), Dr. Londono is funded by a NIH Research Training Program in Basic and Translation Oncology T32 Grant (T32CA183926). Dr. Arend is supported by the Foundation for Women’s Cancer (WeRoc/OChO Ovarian Cancer Research Grant), Norma Livingston Foundation, AAOGF/ ABOG Career Development Award, and ACS-IRG (IRG-60-001-53-IRG). Dr. Hidalgo is supported by the NHLBI Diversity Supplement (HHSN268201300001) and a grant from the Robert Wood Johnson Foundation, New Connections Program.
Original article: Oncotarget. 2016; 7:86803-86815. DOI: https://doi.org/10.18632/oncotarget.13466.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.